WO2005044194A3 - TREATMENT OR PREVENTION OF NEOPLASIA BY USE OF AN Hsp90 INHIBITOR - Google Patents

TREATMENT OR PREVENTION OF NEOPLASIA BY USE OF AN Hsp90 INHIBITOR Download PDF

Info

Publication number
WO2005044194A3
WO2005044194A3 PCT/US2004/036010 US2004036010W WO2005044194A3 WO 2005044194 A3 WO2005044194 A3 WO 2005044194A3 US 2004036010 W US2004036010 W US 2004036010W WO 2005044194 A3 WO2005044194 A3 WO 2005044194A3
Authority
WO
WIPO (PCT)
Prior art keywords
neoplasia
hsp90 inhibitor
prevention
treatment
inhibitor
Prior art date
Application number
PCT/US2004/036010
Other languages
French (fr)
Other versions
WO2005044194A2 (en
Inventor
Jaime L Masferrer
Thomas D Penning
Xing Wang
Deborah M Heuvelman
Original Assignee
Pharmacia Corp
Jaime L Masferrer
Thomas D Penning
Xing Wang
Deborah M Heuvelman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp, Jaime L Masferrer, Thomas D Penning, Xing Wang, Deborah M Heuvelman filed Critical Pharmacia Corp
Publication of WO2005044194A2 publication Critical patent/WO2005044194A2/en
Publication of WO2005044194A3 publication Critical patent/WO2005044194A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles

Abstract

A method for treating or preventing neoplasia or a neoplasia-related disorder in a subject is provided, the method comprising administering to the subject an effective amount of an Hsp90 inhibitor, or of a combination comprising an Hsp90 inhibitor and a Cox-2 inhibitor.
PCT/US2004/036010 2003-10-28 2004-10-28 TREATMENT OR PREVENTION OF NEOPLASIA BY USE OF AN Hsp90 INHIBITOR WO2005044194A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51522503P 2003-10-28 2003-10-28
US60/515,225 2003-10-28

Publications (2)

Publication Number Publication Date
WO2005044194A2 WO2005044194A2 (en) 2005-05-19
WO2005044194A3 true WO2005044194A3 (en) 2005-07-21

Family

ID=34572821

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/036010 WO2005044194A2 (en) 2003-10-28 2004-10-28 TREATMENT OR PREVENTION OF NEOPLASIA BY USE OF AN Hsp90 INHIBITOR

Country Status (1)

Country Link
WO (1) WO2005044194A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9402831B2 (en) 2011-11-14 2016-08-02 Synta Pharmaceutical Corp. Combination therapy of HSP90 inhibitors with BRAF inhibitors

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2594874T3 (en) 2004-11-18 2016-12-23 Synta Pharmaceuticals Corp. Triazole compounds that modulate the activity of HSP90
CN101142198B (en) 2005-02-17 2012-10-31 辛塔制药公司 Isoxazole combretastatin derivatives for the treatment of disorders
US7608635B2 (en) 2005-08-12 2009-10-27 Synta Pharmaceuticals Corp. Pyrazole compounds that modulate HSP90 activity
JP5683787B2 (en) * 2005-08-18 2015-03-11 シンタ ファーマシューティカルズ コーポレーション Imidazole compounds that modulate HSP90 activity
WO2007087427A2 (en) 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Thiazole and thiadiazole compounds for inflammation and immune-related uses
AU2007267860B2 (en) * 2006-05-25 2012-08-09 Synta Pharmaceuticals Corp. Triazole compounds that modulate Hsp90 activity
CA2653217A1 (en) 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Method for treating proliferative disorders associated with protooncogene products
TW200804314A (en) 2006-05-25 2008-01-16 Synta Pharmaceuticals Corp Triazole compounds that modulate Hsp90 activity
JP5441690B2 (en) 2006-05-25 2014-03-12 シンタ ファーマシューティカルズ コーポレーション Triazole compounds that modulate Hsp90 activity
EP2240171B1 (en) * 2008-01-09 2014-08-13 Molecular Insight Pharmaceuticals, Inc. Inhibitors of carbonic anhydrase IX
CN102088973A (en) * 2008-05-15 2011-06-08 杜克大学 Compositions and methods relating to heat shock transcription factor activating compounds and targets thereof
US9315449B2 (en) * 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
AR081810A1 (en) 2010-04-07 2012-10-24 Bayer Cropscience Ag BICYCLE PIRIDINYL PIRAZOLS
EP2560640A1 (en) 2010-04-19 2013-02-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
CN103221388B (en) 2010-07-09 2016-09-28 维理生物技术公司 For the novel sulfonamide compounds suppressing metastatic tumo(u)r to grow
CA2853799A1 (en) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
CA2853806C (en) 2011-11-02 2020-07-14 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with platinum-containing agents
JP6434968B2 (en) 2013-07-02 2018-12-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Tricyclic pyrido-carboxamide derivatives as ROCK inhibitors
US9663529B2 (en) 2013-07-02 2017-05-30 Bristol-Myers Squibb Company Tricyclic pyrido-carboxamide derivatives as rock inhibitors
WO2015031710A1 (en) * 2013-08-29 2015-03-05 Baylor College Of Medicine Compositions and methods for the treatment of metabolic and body weight related disorders
CN105636962B (en) * 2013-10-15 2017-10-13 靳博涵 New compound, purposes and preparation method thereof
EP3237413A4 (en) 2014-12-23 2018-09-12 FGH Biotech Compositions of fatostatin based heterocyclic compounds and uses thereof
CN109476635B (en) 2016-04-29 2021-07-13 Fgh生物科技公司 Disubstituted pyrazoles for treatment of diseases
EP3510027B1 (en) 2016-09-07 2022-11-02 FGH BioTech, Inc. Di-substituted pyrazole compounds for the treatment of diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739166A (en) * 1994-11-29 1998-04-14 G.D. Searle & Co. Substituted terphenyl compounds for the treatment of inflammation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739166A (en) * 1994-11-29 1998-04-14 G.D. Searle & Co. Substituted terphenyl compounds for the treatment of inflammation

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CANCER, vol. 91, no. 5, 1 March 2001 (2001-03-01), pages 940 - 948 *
DATABASE CAPLUS [online] LI J. ET AL: "Novel terphenyls as selective cyclooxgenase-2 inhibitors and orally active anti-inflammatory agents", XP002987258, accession no. stn Database accession no. (124:278412) *
DATABASE MEDLINE [online] DUNPHY F.R. ET AL: "Induction paclitaxel and carboplatin for patients with head and neck carcinoma. Analysis of 62 patients treated between 1994 an 1999", XP002987259, accession no. STN Database accession no. (2001:198884) *
DATABASE MEDLINE [online] KAMATE C. ET AL: "Inflammation and cancer, the mastocytoma P815 tumor model revisited: triggering of macrophage activation in vivo with pro-tumorigenic consequences", XP002987260, accession no. STN Database accession no. (2002:378417) *
INTERNAT J CAN, vol. 100, no. 5, 10 August 2002 (2002-08-10), pages 571 - 579 *
J MEDICINAL CHEM, vol. 39, no. 9, 1996, pages 1846 - 1856 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9402831B2 (en) 2011-11-14 2016-08-02 Synta Pharmaceutical Corp. Combination therapy of HSP90 inhibitors with BRAF inhibitors

Also Published As

Publication number Publication date
WO2005044194A2 (en) 2005-05-19

Similar Documents

Publication Publication Date Title
WO2005044194A3 (en) TREATMENT OR PREVENTION OF NEOPLASIA BY USE OF AN Hsp90 INHIBITOR
WO2005048942A3 (en) Combination therapy comprising a cox-2 inhibitor and an antineoplastic agent
WO2005041879A3 (en) COMBINATIONS COMPRISING AN Hsp90 INHIBITOR AND A PHOPHODIESTERASE INHIBITOR FOR TREATING OR PREVENTING NEOPLASIA
DK1373215T3 (en) Gelanamycin derivatives suitable for the treatment of cancer
WO2005037323A3 (en) Use of gro to treat or prevent inflammation
IL160420A0 (en) Treating or preventing diabetes with cannabidiol
WO2007041398A3 (en) Treatment of cancer with specific rxr agonists
WO2005009342A3 (en) Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
WO2000037107A3 (en) Use of cyclooxygenase-2 inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combination treatment of neoplasia
WO2004045509A3 (en) Method of using a cox-2 inhibitor and a 5-ht1a receptor modulator as a combination therapy
WO2005027993A3 (en) Vascular access preservation in hemodialysis patients
WO2000040235A3 (en) Treatment of asthma with mek inhibitors
WO2002005791A3 (en) Antitumor combination comprising an aromatase inhibitor and an egfr antagonist or inhibitor
WO2003030819A3 (en) Tetracycline derivatives and methods of use thereof
WO2005000213A3 (en) Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors
WO2005082375A3 (en) Treatment of interstitial cystitis with vitamin d compounds
WO2004091540A3 (en) Methods of treating pain and compositions for use therefor
WO2005000212A3 (en) Method for treating diseases using hsp90-inhibiting agents in combination with nuclear export inhibitors
EP1553951A4 (en) Methods of using and compositions comprising a jnk inhibitor for the treatment, prevention, management and/or modification of pain
WO2007120485A3 (en) Methods of treating pain with alkylxanthines and antiepileptics and compositions for use therefor
WO2003092606A3 (en) Cholinesterase inhibitors to prevent injuries caused by chemicals
WO2004096206A3 (en) Therapeutic combination of a cox-2 inhibitor and a tace inhibitor
WO2008016640A3 (en) Use of poloxamer for the prevention and/or treatment of heart failure
WO2004017917A3 (en) Method for the prevention and/or treatment of atherosclerosis
WO2004073615A8 (en) Deazaflavin compounds and methods of use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004796761

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2004796761

Country of ref document: EP

122 Ep: pct application non-entry in european phase